TCI Gene

TCI Gene Current Liabilities

The Current Liabilities of TCI Gene (6879.TWO) as of Nov 3, 2026 is 27.28 M TWD. In the previous year, Current Liabilities was 41.95 M TWD — a change of -34.98% (lower).

Current Liabilities

27.28 MTWD

YoY

-34.98%

Last updated:

Current Liabilities of TCI Gene is 2025 27.28 M TWD. Current Liabilities of TCI Gene was 2024 41.95 M TWD. It decreases by -34.98% lower compared to the previous year.

The TCI Gene Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
60.51 M TWD
Jan 1, 2020
99.25 M TWD
Jan 1, 2021
108.95 M TWD
Jan 1, 2022
96.31 M TWD
Jan 1, 2023
116.85 M TWD
Jan 1, 2024
41.95 M TWD
Jan 1, 2025
27.28 M TWD
The TCI Gene Current Liabilities history
YEARCurrent LiabilitiesYoY
27.28 MTWD-34.98%
41.95 MTWD-64.10%
116.85 MTWD+21.32%
96.31 MTWD-11.60%
108.95 MTWD+9.77%
99.25 MTWD+64.01%
60.51 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TCI Gene Stock analysis

What does TCI Gene do? TCI GENE, Inc. generates revenue through genetic testing services, virus testing services, and cell experiment services. The company produces adipose-derived stem cell preparations for degenerative arthritis and knee cartilage defects, as well as natural killer cell preparations for solid cancer treatment. Personalized genetic health food is also a key product. These offerings are primarily sold within Taiwan, targeting consumers interested in disease risk assessment, drug genetic testing, and personalized health solutions. The firm's comprehensive genetic testing covers areas like child growth, youth beauty, weight management, and cardiovascular drug responses, while pharmacogenetic testing addresses depression and insomnia. The company's product portfolio includes specialized services such as youth beauty genetic testing and anti-aging genetic testing, which appeal to wellness-focused segments. Adipose-derived stem cell preparations are marketed for orthopedic applications, and natural killer cell preparations target cancer patients seeking alternative therapies. Personalized genetic health food is positioned for consumers seeking tailored nutritional support based on genetic profiles. All products are distributed exclusively in Taiwan, with no international market presence mentioned. TCI GENE, Inc. serves customers seeking preventive health management through genetic insights. The primary buyers are individuals in Taiwan interested in disease risk prediction, drug response optimization, and personalized wellness. The firm's focus on genetic health food and cell-based treatments targets health-conscious consumers and patients requiring specialized medical solutions. Sales are concentrated within Taiwan, reflecting the company's localized market strategy. TCI Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TCI Gene stock

Current Liabilities of TCI Gene is 27.28 M TWD in 2025.

Current Liabilities of TCI Gene changed from 41.95 M TWD to 27.28 M TWD, representing a -34.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities TCI Gene since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's TCI Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TCI Gene

All Key Metrics — TCI Gene